Axicabtagene Ciloleucel Injection in Patients With Relapsed/Refractory Follicular Lymphoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 8, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
LymphomaFollicular LymphomaRefractory Lymphoma
Interventions
DRUG

Axicabtagene Ciloleucel

"Pre-treatment chemotherapy: Cyclophosphamide 500 mg/m² and Fludarabine 30 mg/m² will be administered intravenously on Days -5, -4, and -3 (with the day of Axicabtagene Ciloleucel Injection infusion being Day 0).~Axicabtagene Ciloleucel Injection infusion: A single dose of autologous T cells transduced with chimeric antigen receptor (CAR) in the form of Axicabtagene Ciloleucel Injection will be administered to the subject intravenously. The target dose is 2.0×10\^6 anti-CD19 CAR-T cells/kg body weight. The minimum dose that can be used is 1.5×10\^6 anti-CD19 CAR-T cells/kg body weight. For subjects with a body weight of ≥100 kg, the maximum total dose is 2.0×10\^8 anti-CD19 CAR-T cells"

Trial Locations (1)

361003

RECRUITING

Bing Xu, Xiamen

All Listed Sponsors
lead

The First Affiliated Hospital of Xiamen University

OTHER